Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene

Circulation

Volumn 101, Issue 16, 2000, Pages 1907-1912

  Agerholm Larsen, Birgit ^a   Nordestgaard, Børge G ^b,c   Steffensen, Rolf ^d   Jensen, Gorm ^c   Tybjærg Hansen, Anne ^a,c,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

Apolipoproteins; Genetics; Heart diseases; Lipoproteins; Transfer proteins

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; CORONARY RISK; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

EID: 0034712706     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.16.1907     Document Type: Article

References (35)

1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke, JD, Jacobs DR, Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
2. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis. 1996;121:1-12.
3. Breslow JL. Familial disorders of high-density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarden JB, Frederickson DS, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. New York, NY: McGraw-Hill; 1995: 2031-2052.
4. Bruce C, Chouinard RAJ, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr. 1998;18:297-330.
5. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34: 1255-1274.
6. Takahashi K, Jiang XC, Sakai N, Yamashita S, Hirano K, Bujo H, Yamazaki H, Kusunoki J, Miura T, Kussie P, Matsuzawa Y, Saito Y, Tall A. A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. J Clin Invest. 1993;92:2060-2064.
7. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
8. Gudnason V, Kakko S, Nicaud V, Savolainen MJ, Kesaniemi YA, Tahvanainen E, Humphries SE. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. Eur J Clin Invest. 1999;29:116-128.
9. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sørensen TI, Jensen, G, Tybjærg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals: a case-referent and retro-spective cohort study based on the Copenhagen City Heart Study. Circulation. 1997;95:2358-2367.
10. Agerholm-Larsen B, Tybjærg-Hansen A, Frikke-Schmidt R, Grønholdt M-LM, Jensen G, Nordestgaard BG. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. Ann Intern Med. 1997;127: 346-355.
11. Tybjærg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455→A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease: a study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest. 1997;99: 3034-3039.
12. Wittrup HH, Tybjærg-Hansen A, Abildgaard S, Steffensen R, Schnohr P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest. 1997;99:1606-1613.
13. Tybjærg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med. 1998;338:1577-1584.
14. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjærg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997;96:1737-1744.
15. Dahl M, Tybjærg-Hansen A, Lange P, Nordestgaard BG. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet. 1998;351:1911-1913.
16. Nordestgaard BG, Agerholm-Larsen B, Wittrup HH, Tybjærg-Hansen A. A prospective cardiovascular population study used in genetic epidemiology: the Copenhagen City Heart Study. Scand J Clin Lab Invest Suppl 1996;226:65-71.
17. Recommendations of the Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J. 1997;18: 394-413.
18. SPSS for Windows. Base System User's Guide and Advanced Statistics, Release 70. Chicago, Ill: SPSS, Inc; 1996.
19. Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res. 1998;39:1071-1078.
20. Kuivenhoven JA, de Knijff P, Boer JM, Smalheer HA, Botma GJ, Seidell, JC, Kastelein JJ, Pritchard PH. Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol. 1997;17:560-568.
21. Gudnason V, Thormar K, Humphries SE. Interaction of the cholesteryl ester transfer protein I405V polymorphism with alcohol consumption in smoking and non-smoking healthy men, and the effect on plasma HDL cholesterol and apoAI concentration. Clin Genet. 1997;51:15-21.
22. Yamashita S, Hui DY, Sprecher DL, Matsuzawa Y, Sakai N, Tarui S, Kaplan D, Wetterau JR, Harmony JA. Total deficiency of plasma cholesteryl ester transfer protein in subjects homozygous and heterozygous for the intron 14 splicing defect. Biochem Biophys Res Commun. 1990; 170:1346-1351.
23. Makita H, Tsuji M, Furuya Y, Tsuchihashi K, Akita H, Chiba H. A family with complete deficiency of plasma cholesteryl ester transfer protein activities. Intern Med. 1994;33:432-436.
24. Matsunaga A, Araki K, Moriyama K, Handa K, Arakawa F, Nishi K, Sasaki J, Arakawa K. Detection of a point mutation in cholesteryl ester transfer protein gene by polymerase chain reaction-mediated site-directed mutagenesis. Biochim Biophys Acta. 1993;1166:131-134.
25. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053-1059.
26. Havel RJ, Kane JP. Introduction: structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarden JB, Frederickson DS, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed. New York, NY: McGraw-Hill; 1995: 1841-1851.
27. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women: the Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-1075.
28. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, Bush TL. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women: the CHS Collaborative Research Group. Circulation. 1993;88:2163-2171.
29. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
30. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917-2923.
31. Marcel YL, McPherson R, Hogue M, Czarnecka H, Zawadzki Z, Weech PK, Whitlock ME, Tall AR, Milne RW. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest. 1990;85:10-17.
32. Silliman K, Tall AR, Kretchmer N, Forte TM. Unusual high-density lipoprotein subclass distribution during late pregnancy. Metab Clin Exp. 1993;42:1592-1599.
33. Tan KC, Shiu SW, Pang RW, Kung AW. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol. 1998;48:187-194.
34. Buckler HM, McElhone K, Durrington PN, Mackness MI, Ludlam CA, Wu FCW. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol. 1998;49:173-178.
35. Khoury MJ, Beaty TH, Cohen BH. Fundamental epidemiologic concepts and approaches. In: Kelsey JL, Marmot MG, Stolley PD, Vessey MP, eds. Fundamentals of Genetic Epidemiology. New York, NY: Oxford University Press; 1993:77-79.